Gate2Brain
- Biotech or pharma, therapeutic R&D
Gate2Brain: Enabling Brain Delivery of Therapeutics
Gate2Brain is a biotech company developing a proprietary peptide shuttle platform to deliver therapeutics safely and effectively across the blood-brain barrier (BBB). Our technology supports a wide range of modalities—including small molecules, proteins, and nucleic acids—via two mechanisms: transferrin- and caveolin-mediated transcytosis.
Our lead asset, G2B-002, targets DIPG, a fatal pediatric brain tumor, and has received Orphan Drug Designation from the FDA and EMA. It is currently in IND-enabling studies with a planned clinical trial in 2027.
We pursue a dual strategy of internal pipeline development and partnering with pharma to co-develop CNS programs using our platform.
We’re raising a €1.5M Bridge Round (open to early-stage investors) and planning a €10M Series A in 2026 to fund clinical entry and expand the platform.
)
)
){kind=logo}
){kind=logo}
){kind=logo}